Key result
This review summarizes the evidence supporting the use of antiplatelet drugs in various atherothrombotic conditions and highlights concerns inherent in their use.
Why the study?
Do antiplatelet agents modify the natural history of cardiovascular disease in patients with atherothrombotic conditions?
Do antiplatelet agents modify the natural history of cardiovascular disease in patients with atherothrombotic conditions?
This review summarizes the evidence supporting the use of antiplatelet agents in atherothrombotic conditions and outlines concerns inherent in their use.
Answers are grounded in this paper and cite their sources.
May warrant cautious antiplatelet use in atherothrombosis; leaves open optimal agent selection amid evolving therapies.
Platelets play a key role in the pathogenesis of atherothrombotic conditions, e.g. acute coronary syndromes, cerebrovascular and peripheral vascular events. Antiplatelet agents interfere with platelet activation and aggregation and, as such, would be expected to modify the natural history of cardiovascular disease. In this review we explore the evidence to support the use of such drugs, singly or in combination, in a variety of situations characterised by thrombosis and summarise some of the concerns inherent in their use.
No takes yet. Share an insight, caveat, or question.
Clive Weston (2003) conducted a review in Cardiovascular diseases. Antiplatelet drugs was evaluated. This review summarizes the evidence supporting the use of antiplatelet drugs in various atherothrombotic conditions and highlights concerns inherent in their use.
Synapse has enriched 10 related papers. Consider them for comparative context: